Enzyme Engineering Strategies for the Bioenhancement of l-Asparaginase Used as a Biopharmaceutical
- 12 September 2023
- journal article
- review article
- Published by Springer Nature in BioDrugs
- Vol. 37 (6) , 793-811
Abstract
Over the past few years, there has been a surge in the industrial production of recombinant enzymes from microorganisms due to their catalytic characteristics being highly efficient, selective, and biocompatible. l-asparaginase (l-ASNase) is an enzyme belonging to the class of amidohydrolases that catalyzes the hydrolysis of l-asparagine into l-aspartic acid and ammonia. It has been widely investigated as a biologic agent for its antineoplastic properties in treating acute lymphoblastic leukemia. The demand for l-ASNase is mainly met by the production of recombinant type II l-ASNase from Escherichia coli and Erwinia chrysanthemi. However, the presence of immunogenic proteins in l-ASNase sourced from prokaryotes has been known to result in adverse reactions in patients undergoing treatment. As a result, efforts are being made to explore strategies that can help mitigate the immunogenicity of the drug. This review gives an overview of recent biotechnological breakthroughs in enzyme engineering techniques and technologies used to improve anti-leukemic l-ASNase, taking into account the pharmacological importance of l-ASNase. Graphical AbstractKeywords
Funding Information
- FAPESP-UFRO (2020/06982-3)
This publication has 169 references indexed in Scilit:
- PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteinsProtein Engineering, Design and Selection, 2013
- Polyethylene Glycol-conjugated L-asparaginase Versus Native L-asparaginase in Combination With Standard Agents for Children With Acute Lymphoblastic Leukemia in Second Bone Marrow RelapseJournal of Pediatric Hematology/Oncology, 2011
- L‐asparaginase treatment in acute lymphoblastic leukemiaCancer, 2010
- Delivery of Therapeutic ProteinsJournal of Pharmaceutical Sciences, 2010
- Drug delivery by red blood cells: vascular carriers designed by mother natureExpert Opinion on Drug Delivery, 2010
- Design and fabrication of magnetic nanoparticles for targeted drug delivery and imagingAdvanced Drug Delivery Reviews, 2010
- Glycosylation of Therapeutic ProteinsBioDrugs, 2010
- Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase‐associated pancreatitisPediatric Blood & Cancer, 2009
- Heterelogous Expression of Plant GenesInternational Journal of Plant Genomics, 2009
- ElliPro: a new structure-based tool for the prediction of antibody epitopesBMC Bioinformatics, 2008